AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson’s Icotyde, the first oral IL-23 inhibitor on the market. This ...

Shares of AbbVie Inc. ABBV are moving lower Wednesday. The stock appears to be trending down after a competitor announced significant progress made on a treatment for plaque psoriasis. AbbVie shares ...

AbbVie (NYSE: ABBV), a pharmaceutical leader, has faced some challenges over the past three years. The company is managing some patent cliffs and clinical setbacks that worried investors and dinged ...

While Skyrizi’s efficacy and dosing regimen might offer advantages, Icotyde’s approval in the immunology space poses a threat ...

AbbVie’s model based fair value has been adjusted only slightly, moving from US$248.29 to US$248.86, which keeps the overall ...

If you are wondering whether AbbVie is still reasonably priced after a strong multi year run, the key issue is how its current share price compares with different measures of value. AbbVie recently ...

AbbVie (ABBV) stock felt some downward pressure despite reporting better-than-expected fourth-quarter results on Feb. 4. AbbVie beat estimates for both earnings and sales and also issued an upbeat ...

Some valuation metrics suggest that AbbVie is a cheap stock. The company's growth prospects through 2030 look attractive. AbbVie is also an excellent dividend stock. 10 stocks we like better than ...